Possibilities of immunochemical detection of cartilage type II collagen degradation

1. Bauer DC, Hunter DJ, Abramson SB, Attur M, Corr M, Felson D, Heinegard D, Jordan JM, Kepler TB, Lane NE, Saxne T, Tyree B, Kraus VB. Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage 2006; 14: 723–7.

2. Kühn K. The classical collagens: Types I, II, and III. In “Structure and Function of Collagen Types” (Mayne R, Burgeson RE, eds), pp.1–42, Academic Press, Orlando 1987.

3. Kielty CM, Grant ME. The collagen family: structure, assembly, and organization in the extracellular matrix. In “Connective Tissue and Its Heritable Disorders: Molecular, Genetic, and Medical Aspects, 2nd Edition” (Royce PM, Steinmann B, eds), p. 159–221, John Wiley and Sons, Canada, 2002.

4. Gelse K, Pöschl E, Aigner T. Collagens – structure, function, and biosynthesis. Adv Drug Delivery Rev 2003; 55: 1531–46.

5. Dodge GR, Poole AR. Immunohistochemical detection and immunochemical analysis of type II collagen degradation in human normal, rheumatoid, and osteoarthritic articular cartilages and in explants of bovine articular cartilage cultured with interleukin-1. J Clin Invest 1989; 83: 647–61.

6. Dodge GR, Pidoux I, Poole AR. The degradation of type II collagen in rheumatoid arthritis: an immunoelectron microscope study. Matrix 1991; 11: 330–8.

7. Hollander AP, Heathfield TF, Webber C, Iwata Y, Bourne R, Rorabeck C, Poole AR. Increased damage to type II collagen in osteoarthritic articular cartilage detected by a new immunoassay. J Clin Invest 1994; 93: 1722–32.

8. Hollander AP, Pidoux I, Reiner A, Rorabeck C, Bourne R, Poole AR. Damage to type II collagen in aging and osteoarthritis starts at the articular surface, originates around chondrocytes and extends into the cartilage with progressive degeneration. J Clin Incest 1995; 96:2859–69.

9. Croucher LJ, Hollander AP. Differential detection of type II collagen N–terminal and C-terminal denaturation epitopes in degrading cartilage. J Clin Pathol: Mol Pathol 1999; 52: 323-31.

10. Hollander AP, Croucher LJ. Assay for collagen type II fragments. Patent no. WO9835235, 1998.

11. Deberg M, Christgau S, Henriksen D, Cloos P, Colette J, Reginster JY, Henroitin Y. Development of new immunoassay for the quantification of inflammatory related cartilage degradation [abstract]. Arthritis Rheum 2002; 46: S496.

12. Henroitin Y, Deberg M, Dubuc JE, Quettier E, Christgau S, Reginster JY. Type II collagen peptides for measuring cartilage degradation. Biorheology 2004; 41: 543–7.

13. Deberg MA, Labasse AH, Christgau S, Cloos P, Henriksen D, Chapelle JP, Zegels B, Reginster J-Y, Henroitin Y. New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2. for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 2005; 13: 258–65.

14. Deberg MA, Labasse AH, Collette J, Seidel L, Reginster J-Y, Henroitin YE. One-year increase of Coll 2-1, a new marker of type II collagen degradation, in urine is highly predictive of radiological OA progression. Osteoarthritis Cartilage 2005; 13: 1059–65.

15. Charni N, Juillet F, Garnero P. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 2005; 52: 1081–90.

16. Billinghurst RC, Dahlberg L, Ionescu M, Reiner A, Bourne R, Rorabeck C, Mitchell P, Hambor J, Diekmann O, Tschesche H, Chen J, VanWart H, Poole AR. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 1997; 99: 1534–45.

17. Wu W, Billinghurst RC, Pidoux I, Antoniou J, Zukor D, Tanzer M, Poole AR. Sites of collagenase cleavage and denaturation of type II collagen in aging and osteoarthritic articular cartilage and their relationship to the distribution of matrix metalloproteinase 1 and matrix metalloproteinase 13. Arthritis Rheum 2002; 46: 2087–94.

18. Aurich M, Squirez GR, Reiner A, Mollenhauer JA, Kuettner KE, Poole AR, Cole AA. Differential matrix degradation and turnover in early cartilage lesions of human knee and ankle joints. Arthritis Rheum 2005; 52: 112–9.

19. Kojima T, Mwale F, Yasuda T, Girard C, Poole AR, Lavety S. Early degradation of type IX and type II collagen with the onset of experimental inflammatory arthritis. Arthritis Rheum 2001; 44: 120–7.

20. Poole AR, Ionescu M, Fitzcharles MA, Billinghurst RC. The assesment of cartilage degradation in vivo: development of an immunoassay for the measurement in body fluids of type II collagen cleaved by collagenases. J Immunol Met 2004; 294: 145–53.

21. Song X, Zeng L, Jin W, Thompson J, Mizel DE, Lei K, Billinghurst RC, Poole AR, Wahl SM. Secretory leukocyte protease inhibitor suppresses the inflammation and joint damage of bacterial cell wall-induced arthritis. J Exp Med 1999; 190: 535-42.

22. Chu Q, Lopeez M, Hayashi K, Ionescu M, Billinghurst RC, Johnson KA, Poole AR, Markel M. Elevation of a collagenase generated type II collagen neoepitope and proteoglycan epitopes in synovial fluid following induction of joint instability in the dog. Osteoarthritis Cartilage 2002; 10: 662–9.

23. Matyas JR, Atley L, Ionescu M, Eyre DR, Poole AR. Analysis of cartilage biomarkers in the early phases of canine experimental osteoarthritis. Arthritis Rheum 2004; 50: 543–52.

24. Fraser A, Fearon U, Billinghurst RC, Ionescu M, Reece R, Barwick T, Emery P, Poole AR, Veale DJ. Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans – relationship to mediators of systemic and local inflammation. Arthritis Rheum 2003; 48: 3085–95.

25. Cibere J, Thorne A, Kopec JA, Singer J, Canvin J, Robinson DB, Pope J, Hong P, Grant E, Lobanok T, Ionescu M, Poole AR, Esdalle JM. Glucosamine sulfate and cartilage type II collagen degradation in patients with knee osteoarthritis: randomized discontinuation trial results employing biomarkers. J Rheumatol 2005; 32: 896–902.

26. Otterness IG, Downs JT, Lane C, Bliven ML, Stukenbrok H, Scampoli DN, Milici AJ, Mezes PS. Detection of collagenase-induced damage of collagen by 9A4, a monoclonal C-terminal neoepitope antibody. Matrix Biol 1999; 18: 331–41.

27. Downs JT, Lane C, Nestor NB, McLellan TJ, Kelly MA, Karam GA, Mezes PS, Pelletier J-P, Otterness IG. Analysis of collagenase-cleavage of type II collagen using a neoepitope ELISA. J Immunol Met 2001; 247:25–34.

28. Woodworh TG, Otterness IG, Johnson K, Pickering E, Saltarelli MJ. Urinary type II collagen neoepitope (uTIINE) in osteoarthritis (OA) patients is associated with disease severity [abstract]. Arthritis Rheum 1999; 42:S258.

29. Saltarelli MJ, Johnson KS, Pickering E, Otterness IG, Vasquez-Abad MD, Woodworth TG. Measurement of urinary type II collagen neoepitope (uTIINE) levels in rheumatoid arthritis (RA) patients to assess joint status [abstract]. Arthritis Rheum 1999; 42:S249.

30. Pickering E, Vasquez-Abad MD, Saltarelli M, Lorello L, Moctezuma J, Burgos- Vargas R. Assesment of type II collagen neoepitope (TIINE) diurnal variation in urine of patients with rheumatoid arthritis following methotrexate (MTX) initiation [abstract]. Arthritis Rheum 2000; 43: S184.

31. Kraus VB, Stabler T, Le ET, Saltarelli M, Allen NB. Urinary type II collagen neoepitope as an outcome measure for relapsing polychondritis. Arthritis Rheum 2003; 48: 2942–8.

32. Eyre DR. Methods of detecting collagen degradation in vivo. Patent no. WO9108478 1991.

33. Atley LM, Shao P, Shaffer K, Eyre D. Matrix metalloproteinase-mediated release of immunoreactive telopeptides from cartilage type II collagen [abstract]. Trans Orthop Res Soc 1998; 23: 850.

34. Fernandes RJ, Schmid TM, Eyre DR. Assembly of collagen types II, IX and XI into nascent hetero-fibrils by a rat chondrocyte cell line. Eur J Biochem 2003; 270: 3243–50.

35. Eyre DR, Pietka T, Weis MA, Wu JJ. Covalent cross-linking of the NC1 domain of collagen type IX to collagen type II in cartilage. J Biol Chem 2004; 279: 2568–74.

36. Moskowitz RW, Holderbaum D, Atley LM, Eyre DR. Type II collagen C-telopeptide 2B4 epitope is a marker for cartilage degradation in familial osteoarthritis [abstract]. Arthritis Rheum 1998; 41:S352.

37. Lohmander LS, Atley LM, Pietka T, Eyre D. The release of crosslinked peptides from type II collagen into human synovial fluid is increased soon after joint injury and in osteoarthritis. Arthritis Rheum 2003; 48: 3130–9.

38. Christgau S, Garnero P, Fledelius C, Moniz C, Ensig M, Gineyts E, Rosenquist C, Qvist P. Cartilage type II C-telopeptide fragments as an index of cartilage degradation. Bone 2001; 29: 209–15.

39. Reijman N, Hazes JMW, Bierma-Zeinstra SMA, Koes BW, Christgau S, Christiansen C, Uitterlinden AG, Pols HAP. A new marker for osteoarthritis. Cross-sectional and longitudinal approach. Arthritis Rheum 2004; 50: 2471–8.

40. Landewe L, Geusens P, Boers M, van der Heijde D, Lems W, Koppele JT, van der Linden S, Garnero P. Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis. Arthritis Rheum 2004; 50: 1390–9.

41. Mouritzen U, Christgau S, Lehmann HJ, Tanko LB, Chistiansen C. Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index. Ann Rheum Dis 2003; 62: 332–6.

42. Birmingham JD, Vilim V, Kraus VB. Collagen biomarkers for arthritis applications. Biomarker Insights 2006; 1:61–76.